Latest News for: vir

Edit

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

The Eagle-Tribune 24 Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Feb 23, 2026-- ... .
Edit

The Taste by Vir Sanghvi: Why hotels love buffets

Hindustan Times 24 Feb 2026
....
Edit

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager ...

The Daily Sentinel 24 Feb 2026
- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - ... .
Edit

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Pharmiweb 24 Feb 2026
– Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date ... – Vir Biotechnology to host conference call today at 5.30 p.m.
Edit

Third Quarter 2025 10-K (Vir Biotechnology Inc)

Public Technologies 24 Feb 2026
Our patent portfolio includes patents and patent applications that cover our product candidates elebsiran, tobevibart, VIR-5500, VIR-5818, and VIR-5525, and the use of these candidates for therapeutic purposes.
Edit

Fourth Quarter 2025 10-K (Vir Biotechnology Inc)

Public Technologies 24 Feb 2026
Our patent portfolio includes patents and patent applications that cover our product candidates elebsiran, tobevibart, VIR-5500, VIR-5818, and VIR-5525, and the use of these candidates for therapeutic purposes.
Edit

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 ...

The Galveston Daily News 23 Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Feb 23, 2026-- ....
Edit

Notice of Proposed Sale of Securities (Form 144) (Vir Biotechnology Inc)

Public Technologies 23 Feb 2026
). The text version of this document is not available ... Vir Biotechnology Inc.
Edit

Young environmentalist Vir Singh raises awareness on endangered Gharials at Chitkara International School

Hindustan Times 23 Feb 2026
... advocate Vir Singh of the VirVanam Foundation.
Edit

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer (Form 8-K) (Vir Biotechnology Inc)

Public Technologies 23 Feb 2026
) Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer ... - Astellas to lead commercialization of VIR-5500 in the U.S.
Edit

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer

PR Newswire 23 Feb 2026
Vir Biotechnology. - Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - ... Naoki Okamura, "Astellas") and Vir Biotechnology, Inc ... About Vir Biotechnology, Inc.Vir Biotechnology, Inc.
Edit

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results (Vir Biotechnology Inc)

Public Technologies 23 Feb 2026
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results ... Reports updated VIR-5500 Phase 1 dose-escalation data supporting a favorable safety pro le and promising anti-tumor activity ... VIR-5500.
Edit

Initial Registration Statement for Employee Benefit Plan (Form S-8) (Vir Biotechnology Inc)

Public Technologies 23 Feb 2026
Vir Biotechnology, Inc ... Vir Biotechnology, Inc ... Vir Biotechnology, Inc ... 2019 Equity Incentive Plan (the "Incentive Plan") and an additional 1,394,749 shares of Common Stock under the Vir Biotechnology, Inc ... 4.4 Vir Biotechnology, Inc.
Edit

Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K) (Vir Biotechnology Inc)

Public Technologies 23 Feb 2026
Unless the context requires otherwise, references in this Annual Report on Form 10-K to the "Company", "Vir Bio," "we," "our" and "us" refer to Vir Biotechnology, Inc ... VIR-5500 ... VIR-5818 ... VIR-5525.
Edit

Rude Health by Vir Sanghvi: Time to see a shrink

Hindustan Times 20 Feb 2026
Ozempic and Mounjaro have ...

Article Search

tools
×
×
×
×